RYTHM (NASDAQ:RYM – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare RYTHM to related companies based on the strength of its risk, profitability, valuation, dividends, earnings, analyst recommendations and institutional ownership.
Institutional & Insider Ownership
6.0% of RYTHM shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 3.5% of RYTHM shares are owned by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent ratings for RYTHM and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| RYTHM | 1 | 0 | 0 | 0 | 1.00 |
| RYTHM Competitors | 7844 | 13796 | 25806 | 1039 | 2.41 |
As a group, “Pharmaceuticals” companies have a potential upside of 24.69%. Given RYTHM’s peers stronger consensus rating and higher possible upside, analysts plainly believe RYTHM has less favorable growth aspects than its peers.
Profitability
This table compares RYTHM and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| RYTHM | 9.84% | 21.25% | 5.51% |
| RYTHM Competitors | -2,400.69% | -221.80% | -15.58% |
Earnings and Valuation
This table compares RYTHM and its peers top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| RYTHM | $17.28 million | -$33.26 million | -2.61 |
| RYTHM Competitors | $3.57 billion | $3.20 billion | 562.76 |
RYTHM’s peers have higher revenue and earnings than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
RYTHM has a beta of 9.94, meaning that its stock price is 894% more volatile than the S&P 500. Comparatively, RYTHM’s peers have a beta of -0.13, meaning that their average stock price is 113% less volatile than the S&P 500.
Summary
RYTHM peers beat RYTHM on 9 of the 13 factors compared.
RYTHM Company Profile
I couldn’t verify a Nasdaq-listed company named RYTHM with the ticker RYM. If you mean Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM), it is a biopharmaceutical company developing treatments for rare genetic diseases and other conditions linked to the brain’s melanocortin-4 receptor pathway, which helps regulate hunger and body weight. Its marketed medicine, Imcivree (setmelanotide), is approved in the United States for certain forms of rare genetic obesity and acquired hypothalamic obesity. The company is based in Boston and focuses on developing and providing therapies for patients in the United States and other markets.
Receive News & Ratings for RYTHM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RYTHM and related companies with MarketBeat.com's FREE daily email newsletter.
